Literature DB >> 11369154

Psychosocial care in family cancer clinics in The Netherlands: a brief report.

E M Bleiker1, F J Grosfeld, D E Hahn, C Honing.   

Abstract

The present survey was undertaken to obtain a better understanding of the organisation of standard psychosocial services at the family cancer clinics in The Netherlands. Colleagues at the nine family cancer clinics in The Netherlands completed a brief questionnaire. It was found that all clinics offered professional psychosocial support for asymptomatic women from hereditary breast-ovarian cancer (HBOC) families. On average, one half-time psychosocial worker (usually a social worker and/or a psychologist) was involved in the genetic counselling. All clinics have developed education material about HBOC independently. As a result of the survey, an effort is made to coordinate the development of education material. Furthermore, it is concluded that more attention should be paid to symptomatic mutation carriers and those individuals, who receive inconclusive genetic test results. These subgroups are usually excluded from the protocols for psychosocial care in genetic counselling.

Entities:  

Mesh:

Year:  2001        PMID: 11369154     DOI: 10.1016/s0738-3991(01)00119-7

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  2 in total

1.  Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Authors:  Karin M Landsbergen; Judith B Prins; Yvonne J L Kamm; Han G Brunner; Nicoline Hoogerbrugge
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

2.  Psycho-social counselling in predictive genetic testing for cancer: the association between number of supportive sessions and client characteristics as assessed by psycho-social workers.

Authors:  E D Mollema; E M A Smets; M E Richard; A M Schiphorst; N J Leschot
Journal:  J Genet Couns       Date:  2008-08-27       Impact factor: 2.537

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.